BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 24582303)

  • 1. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches.
    Beal K; Abrey LE; Gutin PH
    Radiat Oncol; 2011 Jan; 6():2. PubMed ID: 21214925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).
    Gately L; Mesía C; Sepúlveda JM; Del Barco S; Pineda E; Gironés R; Fuster J; Dumas M; Gill S; Navarro LM; Herrero A; Dowling A; de Las Peñas R; Vaz MA; Alonso M; Lwin Z; Harrup R; Peralta S; Long A; Perez-Segura P; Ahern E; Garate CO; Wong M; Campbell R; Cuff K; Jennens R; Gallego O; Underhill C; Martinez-Garcia M; Covela M; Cooper A; Brown S; Rosenthal M; Torres J; Collins IM; Gibbs P; Balana C
    J Neurooncol; 2024 Jun; 168(2):299-306. PubMed ID: 38630385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma in the elderly: treatment patterns and survival.
    Pretanvil JA; Salinas IQ; Piccioni DE
    CNS Oncol; 2017 Jan; 6(1):19-28. PubMed ID: 28001088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Reply to the Letter to the Editor Regarding "Palliative Care Effects on Survival in Glioblastoma: Who Receives Palliative Care?".
    Pando A
    World Neurosurg; 2023 May; 173():296. PubMed ID: 37189316
    [No Abstract]   [Full Text] [Related]  

  • 5. Palliative care in glioblastoma patients: a systematic review.
    Coronatto LH; Formentin C
    Rev Assoc Med Bras (1992); 2024; 70(suppl 1):e2024S122. PubMed ID: 38865542
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter to the Editor Regarding: "Palliative Care Effects on Survival in Glioblastoma: Who Receives Palliative Care?".
    Shlobin NA; Bernstein M
    World Neurosurg; 2023 May; 173():294-295. PubMed ID: 37189315
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapy for glioblastoma patients with poor performance status.
    Schröder C; Gramatzki D; Vu E; Guckenberger M; Andratschke N; Weller M; Hertler C
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2127-2136. PubMed ID: 34448057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating glioblastoma patients with poor performance status: where do we go from here?
    Gállego Pérez-Larraya J; Ducray F
    CNS Oncol; 2014 May; 3(3):231-41. PubMed ID: 25055131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
    Badaoui N; Meyronet D; Cartalat-Carel S; Guyotat J; Jouanneau E; d'Hombres A; Sunyach MP; Jouvet A; Louis-Tisserand G; Archinet A; Frappaz D; Bauchet L; Honnorat J; Ducray F
    Rev Neurol (Paris); 2014 Mar; 170(3):222-7. PubMed ID: 24582303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
    Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
    Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
    Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
    N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.